Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Non-cash Items (2016 - 2025)

Cytokinetics (CYTK) has disclosed Non-cash Items for 13 consecutive years, with $305.4 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items changed N/A to $305.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $305.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at $305.4 million for FY2025, N/A changed from the prior year.
  • Non-cash Items for Q4 2025 was $305.4 million at Cytokinetics, down from $676.4 million in the prior quarter.
  • The five-year high for Non-cash Items was $676.4 million in Q4 2023, with the low at $200000.0 in Q3 2022.
  • Average Non-cash Items over 4 years is $142.1 million, with a median of $5.8 million recorded in 2021.
  • The sharpest move saw Non-cash Items increased 2.18% in 2021, then soared 10891.72% in 2023.
  • Over 4 years, Non-cash Items stood at $5.8 million in 2021, then increased by 5.57% to $6.2 million in 2022, then skyrocketed by 10891.72% to $676.4 million in 2023, then crashed by 54.85% to $305.4 million in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $305.4 million, $676.4 million, and $6.2 million for Q4 2025, Q4 2023, and Q4 2022 respectively.